Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Clinical assessment of 5-fluorouracil/leucovorin, nab-paclitaxel, and irinotecan(FOLFIRABRAX) in untreated gastrointestinal cancer patients using UGT1A1 genotype-guided dosing.

Joshi S, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, Sehdev A, Wade J, Sadiq A, Picozzi VJ, Amico A, Marsh R, Kozloff MF, Polite B, Kindler H, Sharma MR.

Clin Cancer Res. 2019 Sep 26. pii: clincanres.1483.2019. doi: 10.1158/1078-0432.CCR-19-1483. [Epub ahead of print]

PMID:
31558477
2.

Phase II trial of neoadjuvant FOLFIRINOX and IMRT concurrent with FDR-gemcitabine in patients with borderline resectable pancreatic cancer.

Tran NH, Sahai V, Griffith KA, Nathan H, Kaza R, Cuneo KC, Shi J, Kim E, Sonnenday CJ, Cho CS, Lawrence TS, Zalupski MM.

Int J Radiat Oncol Biol Phys. 2019 Sep 5. pii: S0360-3016(19)33746-0. doi: 10.1016/j.ijrobp.2019.08.057. [Epub ahead of print]

PMID:
31494181
3.

Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.

Cuneo KC, Morgan MA, Sahai V, Schipper MJ, Parsels LA, Parsels JD, Devasia T, Al-Hawaray M, Cho CS, Nathan H, Maybaum J, Zalupski MM, Lawrence TS.

J Clin Oncol. 2019 Oct 10;37(29):2643-2650. doi: 10.1200/JCO.19.00730. Epub 2019 Aug 9.

PMID:
31398082
4.

Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, Munshi HG, Benson AB 3rd, O'Dwyer PJ.

JAMA Oncol. 2018 Dec 1;4(12):1707-1712. doi: 10.1001/jamaoncol.2018.3277.

5.

Irinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies.

Zhen DB, McDevitt RL, Zalupski MM, Sahai V.

J Oncol Pharm Pract. 2019 Jun;25(4):980-986. doi: 10.1177/1078155218763044. Epub 2018 Mar 21.

PMID:
29562843
6.

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.

Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE.

J Clin Oncol. 2018 Feb 1;36(4):359-366. doi: 10.1200/JCO.2017.74.9564. Epub 2017 Dec 12.

PMID:
29232172
7.

Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy.

Cuneo KC, Morgan MA, Griffith KA, Hawkins PG, Greenson JK, Ben-Josef E, Lawrence TS, Zalupski MM.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):490-497. doi: 10.1016/j.ijrobp.2017.10.030. Epub 2017 Oct 28.

8.

Integrative clinical genomics of metastatic cancer.

Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, Schuetze S, Alva A, Siddiqui J, Chugh R, Worden F, Zalupski MM, Innis J, Mody RJ, Tomlins SA, Lucas D, Baker LH, Ramnath N, Schott AF, Hayes DF, Vijai J, Offit K, Stoffel EM, Roberts JS, Smith DC, Kunju LP, Talpaz M, Cieślik M, Chinnaiyan AM.

Nature. 2017 Aug 17;548(7667):297-303. doi: 10.1038/nature23306. Epub 2017 Aug 2.

9.

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.

Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A.

Br J Cancer. 2017 Feb 28;116(5):575-583. doi: 10.1038/bjc.2017.10. Epub 2017 Feb 2.

10.

SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy.

Davis EJ, Zhao L, Lucas DR, Schuetze SM, Baker LH, Zalupski MM, Thomas D, Chugh R.

BMC Cancer. 2016 Aug 20;16:663. doi: 10.1186/s12885-016-2694-2.

11.

A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.

Zhen DB, Griffith KA, Ruch JM, Camphausen K, Savage JE, Kim EJ, Sahai V, Simeone DM, Zalupski MM.

Invest New Drugs. 2016 Dec;34(6):733-739. Epub 2016 Jul 21.

PMID:
27439894
12.

A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma.

Cohen SJ, Zalupski MM, Conkling P, Nugent F, Ma WW, Modiano M, Pascual R, Lee FC, Wong L, Hersh E.

Am J Clin Oncol. 2018 Mar;41(3):230-235. doi: 10.1097/COC.0000000000000260.

PMID:
26709865
13.

A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.

Davis EJ, Griffith KA, Kim EJ, Ruch JM, McDonnell KJ, Zalupski MM.

Am J Clin Oncol. 2018 Feb;41(2):128-132. doi: 10.1097/COC.0000000000000240.

14.

Definitive Chemoradiation With Full-dose Gemcitabine for Unresectable Pancreatic Cancer: Efficacy of Involved-Field Radiotherapy.

Zhou J, Fang CX, Shen J, Schipper MJ, Zalupski MM, Minter RM, Simeone DM, Hart D, Eagle T, Kimmel GW, Vainshtein J, Lawrence TS, Feng M.

Am J Clin Oncol. 2017 Oct;40(5):517-522. doi: 10.1097/COC.0000000000000200.

PMID:
26165418
15.

A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.

Davis EJ, Chugh R, Zhao L, Lucas DR, Biermann JS, Zalupski MM, Feng M, Wong SL, Jacobson J, Zyczynski L, Reinke D, Metko G, Baker LH, Schuetze SM.

Eur J Cancer. 2015 Sep;51(13):1794-802. doi: 10.1016/j.ejca.2015.05.010. Epub 2015 Jun 9.

PMID:
26066736
16.

Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer.

Chatterjee M, Ben-Josef E, Thomas DG, Morgan MA, Zalupski MM, Khan G, Andrew Robinson C, Griffith KA, Chen CS, Ludwig T, Bekaii-Saab T, Chakravarti A, Williams TM.

Sci Rep. 2015 Jun 12;5:10867. doi: 10.1038/srep10867.

17.

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.

Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, Thomas CR Jr, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD.

J Clin Oncol. 2015 Aug 20;33(24):2617-22. doi: 10.1200/JCO.2014.60.2219. Epub 2015 May 11.

18.

Implication of suspicious cytology in endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer.

Shi J, Lew M, Zalupski MM, Roh MH, Kwon RS, Pang JC.

J Gastrointest Cancer. 2015 Mar;46(1):54-9. doi: 10.1007/s12029-014-9681-0.

PMID:
25576465
19.

DEPTOR has growth suppression activity against pancreatic cancer cells.

Li H, Sun GY, Zhao Y, Thomas D, Greenson JK, Zalupski MM, Ben-Josef E, Sun Y.

Oncotarget. 2014 Dec 30;5(24):12811-9.

20.

A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer.

Cuneo KC, Chenevert TL, Ben-Josef E, Feng MU, Greenson JK, Hussain HK, Simeone DM, Schipper MJ, Anderson MA, Zalupski MM, Al-Hawary M, Galban CJ, Rehemtulla A, Feng FY, Lawrence TS, Ross BD.

Transl Oncol. 2014 Oct 24;7(5):644-9. doi: 10.1016/j.tranon.2014.07.005. eCollection 2014 Oct.

21.

Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.

Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, Khan GN, Blau JL, Craig R, Balis UG, Zalupski MM, Simeone DM.

Clin Cancer Res. 2014 Dec 1;20(23):5937-5945. doi: 10.1158/1078-0432.CCR-14-1269. Epub 2014 Oct 2.

22.

Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.

Serrano PE, Herman JM, Griffith KA, Zalupski MM, Kim EJ, Bekaii-Saab TS, Ben-Josef E, Dawson LA, Ringash J, Wei AC.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):270-7. doi: 10.1016/j.ijrobp.2014.05.053. Epub 2014 Aug 4.

23.

Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma.

Welling TH, Feng M, Wan S, Hwang SY, Volk ML, Lawrence TS, Zalupski MM, Sonnenday CJ.

Liver Transpl. 2014 Jan;20(1):81-8. doi: 10.1002/lt.23757. Epub 2013 Nov 21.

24.

A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.

Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, Laheru D, Wolfgang CL, Williams T, Bloomston M, Moore MJ, Wei A, Zalupski MM.

Cancer. 2013 Aug 1;119(15):2692-700. doi: 10.1002/cncr.28117. Epub 2013 May 29.

25.

Identification of targetable FGFR gene fusions in diverse cancers.

Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, Roychowdhury S, Hussain MH, Feng FY, Zalupski MM, Talpaz M, Pienta KJ, Rhodes DR, Robinson DR, Chinnaiyan AM.

Cancer Discov. 2013 Jun;3(6):636-47. doi: 10.1158/2159-8290.CD-13-0050. Epub 2013 Apr 4.

26.

Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.

Vainshtein JM, Schipper M, Zalupski MM, Lawrence TS, Abrams R, Francis IR, Khan G, Leslie W, Ben-Josef E.

Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):96-101. doi: 10.1016/j.ijrobp.2012.11.020. Epub 2012 Dec 19.

27.

A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.

Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA.

Clin Cancer Res. 2013 Jan 1;19(1):258-67. doi: 10.1158/1078-0432.CCR-12-1800. Epub 2012 Oct 18.

28.

The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer.

Herman JM, Narang AK, Griffith KA, Zalupski MM, Reese JB, Gearhart SL, Azad NS, Chan J, Olsen L, Efron JE, Lawrence TS, Ben-Josef E.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e15-9. doi: 10.1016/j.ijrobp.2012.09.006. Epub 2012 Oct 9.

29.

Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.

Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, Bekaii-Saab T.

Cancer. 2013 Jan 15;119(2):285-92. doi: 10.1002/cncr.27734. Epub 2012 Jul 11.

30.

A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.

Ben-Josef E, Schipper M, Francis IR, Hadley S, Ten-Haken R, Lawrence T, Normolle D, Simeone DM, Sonnenday C, Abrams R, Leslie W, Khan G, Zalupski MM.

Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1166-71. doi: 10.1016/j.ijrobp.2012.02.051. Epub 2012 Apr 27.

31.

Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma.

Schuetze SM, Zhao L, Chugh R, Thomas DG, Lucas DR, Metko G, Zalupski MM, Baker LH.

Eur J Cancer. 2012 Jun;48(9):1347-53. doi: 10.1016/j.ejca.2012.03.022. Epub 2012 Apr 21.

PMID:
22525224
32.

Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma.

Ha HT, Griffith KA, Zalupski MM, Schuetze SM, Thomas DG, Lucas DR, Baker LH, Chugh R.

Am J Clin Oncol. 2013 Feb;36(1):77-82. doi: 10.1097/COC.0b013e31823a4970.

PMID:
22237145
33.

Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.

Hunter KU, Feng FY, Griffith KA, Francis IR, Lawrence TS, Desai S, Murphy JD, Zalupski MM, Ben-Josef E.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):921-6. doi: 10.1016/j.ijrobp.2011.08.022. Epub 2011 Dec 28.

PMID:
22208966
34.

Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.

Kim EJ, Zalupski MM.

J Surg Oncol. 2011 Dec;104(8):901-6. doi: 10.1002/jso.21872. Review.

35.

Retroperitoneal germ cell tumor diagnosed by endoscopic ultrasound-guided fine needle aspiration.

Womeldorph CM, Zalupski MM, Knoepp SM, Soltani M, Elmunzer BJ.

World J Gastrointest Oncol. 2010 Dec 15;2(12):443-5. doi: 10.4251/wjgo.v2.i12.443.

36.

CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.

Hammad N, Heilbrun LK, Philip PA, Shields AF, Zalupski MM, Venkatramanamoorthy R, El-Rayes BF.

Asia Pac J Clin Oncol. 2010 Jun;6(2):98-105. doi: 10.1111/j.1743-7563.2010.01290.x.

37.

A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.

Cohen SJ, Zalupski MM, Modiano MR, Conkling P, Patt YZ, Davis P, Dorr RT, Boytim ML, Hersh EM.

Cancer Chemother Pharmacol. 2010 Jul;66(2):287-94. doi: 10.1007/s00280-009-1162-y. Epub 2009 Oct 24.

38.

Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.

Choi M, Heilbrun LK, Venkatramanamoorthy R, Lawhorn-Crews JM, Zalupski MM, Shields AF.

Am J Clin Oncol. 2010 Jun;33(3):257-61. doi: 10.1097/COC.0b013e3181a76a0b.

39.

An unusual case of small cell carcinoma of the anal canal.

Khan GN, Siddiqui M, Ben-Josef E, Zalupski MM.

Am J Clin Oncol. 2009 Oct;32(5):543-4. No abstract available.

PMID:
23061097
40.

Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.

Desai S, Ben-Josef E, Griffith KA, Simeone D, Greenson JK, Francis IR, Hampton J, Colletti L, Chang AE, Lawrence TS, Zalupski MM.

Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1450-5. doi: 10.1016/j.ijrobp.2009.01.023. Epub 2009 May 4.

PMID:
19409732
41.

A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.

Gartner EM, Griffith KA, Pan Q, Brewer GJ, Henja GF, Merajver SD, Zalupski MM.

Invest New Drugs. 2009 Apr;27(2):159-65. doi: 10.1007/s10637-008-9165-9. Epub 2008 Aug 20.

42.

Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.

Small W Jr, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ.

J Clin Oncol. 2008 Feb 20;26(6):942-7. doi: 10.1200/JCO.2007.13.9014.

PMID:
18281668
43.

Radiotherapy for locally advanced pancreatic cancer.

Ben-Josef E, Lawrence TS, Zalupski MM.

J Clin Oncol. 2007 Oct 20;25(30):4861. No abstract available.

PMID:
17947742
44.

Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer.

Desai SP, Ben-Josef E, Normolle DP, Francis IR, Greenson JK, Simeone DM, Chang AE, Colletti LM, Lawrence TS, Zalupski MM.

J Clin Oncol. 2007 Oct 10;25(29):4587-92.

PMID:
17925553
45.

A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.

Desai SP, El-Rayes BF, Ben-Josef E, Greenson JK, Knol JA, Huang EH, Griffith KA, Philip PA, McGinn CJ, Zalupski MM.

Am J Clin Oncol. 2007 Aug;30(4):340-5.

PMID:
17762432
46.

Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.

Schneider BJ, El-Rayes B, Muler JH, Philip PA, Kalemkerian GP, Griffith KA, Zalupski MM.

Cancer. 2007 Aug 15;110(4):770-5.

47.

Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.

Chugh R, Wagner T, Griffith KA, Taylor JM, Thomas DG, Worden FP, Leu KM, Zalupski MM, Baker LH.

Cancer. 2007 Jun 1;109(11):2315-22.

48.

Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.

El-Rayes BF, Zalupski MM, Manza SG, Rusin B, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Shields AF, Philip PA.

Cancer Chemother Pharmacol. 2008 Feb;61(2):283-9. Epub 2007 Apr 12.

49.

Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer.

Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E.

Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):801-8. Epub 2007 Mar 26.

PMID:
17379445
50.

Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.

Von Burton G, Rankin C, Zalupski MM, Mills GM, Borden EC, Karen A.

Am J Clin Oncol. 2006 Feb;29(1):59-61.

PMID:
16462504

Supplemental Content

Loading ...
Support Center